- •Diabetic Retinopathy
- •Preface
- •Acknowledgments
- •Contents
- •Contributors
- •Pathophysiology of Diabetic Retinopathy
- •1.1 Retinal Anatomy
- •1.1.1 History
- •1.1.2 Anatomy
- •1.1.3 Microanatomy of the Retina Neurons
- •1.1.4 Intercellular Spaces
- •1.1.5 Internal Limiting Membrane
- •1.1.6 Circulation
- •1.1.7 Arteries
- •1.1.8 Veins
- •1.1.9 Capillaries
- •1.2 Hemodynamics, Macular Edema, and Starling’s Law
- •1.3 Biochemical Basis for Diabetic Retinopathy
- •1.3.1 Increased Polyol Pathway Flux
- •1.3.2 Advanced Glycation End Products (AGEs)
- •1.3.3 Activation of Protein Kinase C (PKC)
- •1.3.4 Increased Hexosamine Pathway Flux
- •1.4 Macular Edema
- •1.5 Development of Proliferative Diabetic Retinopathy
- •1.6 Summary of Key Points
- •1.7 Future Directions
- •References
- •Genetics and Diabetic Retinopathy
- •2.1 Background for Clinical Genetics
- •2.2 The Role of Polymorphisms in Genetic Studies
- •2.3 Types of Genetic Study Design
- •2.4 Studies of the Genetics of Diabetic Retinopathy
- •2.4.1 Clinical Studies
- •2.4.2 Molecular Genetic Studies
- •2.4.3 EPO Promoter
- •2.4.4 Aldose Reductase Gene
- •2.4.5 VEGF Gene
- •2.5 Genes in or Near the HLA Locus
- •2.6 Receptor for Advanced Glycation End Products (RAGE) Genes
- •2.7 Endothelial NOS2 and NOS3 Genes
- •2.9 Solute Carrier Family 2 (Facilitated Glucose Transporter), Member 1 Gene (SLC2A1)
- •2.11 Potential Value of Identifying Genetic Associations with Diabetic Retinopathy
- •2.12 Summary of Key Points
- •2.13 Future Directions
- •Glossary
- •References
- •Epidemiology of Diabetic Retinopathy
- •3.1 Introduction and Definitions
- •3.2 Epidemiology of Diabetes Mellitus
- •3.3 Factors Influencing the Prevalence of Diabetes Mellitus
- •3.4 Epidemiology of Diabetic Retinopathy
- •3.5 Diabetes and Visual Loss
- •3.6 Prevalence and Incidence of Diabetic Retinopathy
- •3.7 By Diabetes Type
- •3.8 By Insulin Use
- •3.10 By Duration of Diabetes Mellitus
- •3.11 By Ethnicity
- •3.12 Gender
- •3.13 Age at Onset of Diabetes
- •3.14 Socioeconomic Status and Educational Level
- •3.15 Family History of Diabetes
- •3.16 Changes Over Time
- •3.17 Epidemiology of Diabetic Macular Edema (DME)
- •3.18 Epidemiology of Proliferative Diabetic Retinopathy (PDR)
- •3.19 Socioeconomic Impact of Diabetes
- •3.20 Socioeconomic Impact of Diabetic Retinopathy
- •3.21 Summary of Key Points
- •3.22 Future Directions
- •References
- •Systemic and Ocular Factors Influencing Diabetic Retinopathy
- •4.1 Introduction
- •4.2 Systemic Factors
- •4.2.1 Glycemic Control
- •4.2.1.1 Type 1 Diabetes Mellitus
- •4.2.1.2 Type 2 Diabetes Mellitus
- •4.2.1.3 Rapidity of Improvement in Glycemic Control
- •4.2.2 Glycemic Variability
- •4.2.3 Insulin Use in Type 2 Diabetes
- •4.2.5 Blood Pressure
- •4.2.6 Serum Lipids
- •4.2.7 Anemia
- •4.2.8 Nephropathy
- •4.2.9 Pregnancy
- •4.2.10 Other Systemic Factors
- •4.2.11 Influence on Visual Loss
- •4.3 Effects of Systemic Drugs
- •4.3.1 Diuretics
- •4.3.3 Aldose Reductase Inhibitors
- •4.3.4 Drugs That Target Platelets
- •4.3.5 Statins
- •4.3.6 Protein Kinase C Inhibitors
- •4.3.7 Thiazolidinediones (Glitazones)
- •4.3.8 Miscellaneous Drugs
- •4.4 Ocular Factors Influencing Diabetic Retinopathy
- •4.6 Economic Consequences
- •4.7 Summary of Key Points
- •4.8 Future Directions
- •References
- •Defining Diabetic Retinopathy Severity
- •5.1 Summary of Key Points
- •5.2 Future Directions
- •5.3 Practice Exercises
- •References
- •6.1 Optical Coherence Tomography (OCT)
- •6.2 Heidelberg Retinal Tomograph (HRT)
- •6.3 Retinal Thickness Analyzer (RTA)
- •6.4 Microperimetry
- •6.5 Color Fundus Photography
- •6.6 Fluorescein Angiography
- •6.7 Ultrasonography
- •6.8 Multifocal ERG
- •6.9 Miscellaneous Modalities
- •6.10 Summary of Key Points
- •6.11 Future Directions
- •6.12 Practice Exercises
- •References
- •Diabetic Macular Edema
- •7.1 Epidemiology and Risk Factors
- •7.2 Pathophysiology and Pathoanatomy
- •7.2.1 Anatomy
- •7.3 Physiology
- •7.4 Clinical Definitions
- •7.5 Focal and Diffuse Diabetic Macular Edema
- •7.6 Subclinical Diabetic Macular Edema
- •7.7 Refractory Diabetic Macular Edema
- •7.8 Regressed Diabetic Macular Edema
- •7.9 Recurrent Diabetic Macular Edema
- •7.10 Methods of Detection of Diabetic Macular Edema
- •7.11 Case Report 1
- •7.12 Case Report 2
- •7.13 Other Ancillary Studies in Diabetic Macular Edema
- •7.14 Natural History
- •7.15 Treatments
- •7.15.1 Metabolic Control and Effects of Drugs
- •7.16 Focal/Grid Laser Photocoagulation
- •7.16.1 ETDRS Treatment of CSME
- •7.17 Evolution in Focal/Grid Laser Treatment Since the ETDRS
- •7.18 Macular Thickness Outcomes After Focal/Grid Photocoagulation
- •7.19 Resolution of Lipid Exudates After Focal/Grid Laser Photocoagulation
- •7.20 Inconsistency in Defining Refractory Diabetic Macular Edema
- •7.21 Alternative Forms of Laser Treatment for Diabetic Macular Edema
- •7.22 Peribulbar Triamcinolone Injection
- •7.23 Intravitreal Triamcinolone Injection
- •7.24 Intravitreal Dexamethasone Delivery System
- •7.27 Combined Intravitreal and Peribulbar Triamcinolone and Focal Laser Therapy
- •7.28 Vitrectomy
- •7.29 Supplemental Oxygen and Hyperbaric Oxygenation
- •7.30 Resection of Subfoveal Hard Exudates
- •7.31 Subclinical Diabetic Macular Edema
- •7.32 Cases with Simultaneous Indications for Focal and Scatter Laser Photocoagulation
- •7.34 Factors Influencing Treatment of Diabetic Macular Edema
- •7.35 Sequence of Therapy
- •7.36 Interaction of Cataract Surgery and Diabetic Macular Edema
- •7.37 Summary of Key Points
- •7.38 Future Directions
- •References
- •Diabetic Macular Ischemia
- •8.1 Introduction
- •8.2 Pathogenesis, Anatomy, and Physiology
- •8.3 Natural History
- •8.4 Clinical Evaluation
- •8.5 Clinical Significance of Diabetic Macular Ischemia
- •8.6 Controversies and Conundrums
- •8.7 Summary of Key Points
- •8.8 Future Directions
- •References
- •Treatment of Proliferative Diabetic Retinopathy
- •9.1 Introduction
- •9.2 Laser Photocoagulation
- •9.2.1 Indications
- •9.2.2 PRP Technique
- •9.2.3 Complications
- •9.2.4 Outcome
- •9.3 Intraocular Pharmacological Therapy
- •9.4 Vitreoretinal Surgery
- •9.4.1 Indications
- •9.4.2 Preoperative Management
- •9.4.3 Instrumentation
- •9.4.4 Techniques
- •9.4.5 Postoperative Management
- •9.4.6 Complications
- •9.4.7 General Outcome
- •9.5 Follow-Up Considerations in PDR
- •9.6.1 Cataract and PDR
- •9.6.2 Dense Vitreous Hemorrhage and Untreated PDR
- •9.6.3 Untreated PDR with Diabetic Macular Edema
- •9.6.4 PDR with Severe Fibrovascular Proliferation/Traction Retinal Detachment
- •9.6.5 PDR with Neovascular Glaucoma
- •9.6.6 Conditions Altering the Clinical Course of PDR
- •9.7 Summary of Key Points
- •9.8 Future Directions
- •References
- •Cataract Surgery and Diabetic Retinopathy
- •10.1 Scope of the Problem of Diabetic Retinopathy Concomitant with Surgical Cataract
- •10.2 Visual Outcomes After Cataract Surgery in Patients with Diabetic Retinopathy
- •10.3 Postoperative Course and Special Considerations After Cataract Surgery in Patients with Diabetic Retinopathy
- •10.4 The Influence of Cataract Surgery on Diabetic Retinopathy
- •10.5 The Role of Ancillary Testing in Managing Cataract Surgery in Eyes with Diabetic Retinopathy
- •10.6 Candidate Risk and Protective Factors for Diabetic Macular Edema Induction or Exacerbation Following Cataract Surgery and Suggested Management Actions
- •10.7 The Problem of Adherence to Preferred Practice Guidelines
- •10.8 Management of the Diabetic Eye Without Macular Edema About to Undergo Cataract Surgery
- •10.9 Treatment of Diabetic Macular Edema Detected Before Cataract Surgery When the Macular View Is Clear
- •10.10 Management When Cataract Sufficient to Obscure the Macular View and DME Coexist or When Refractory DME and Cataract Coexist
- •10.11 Patients with Simultaneous Indications for Panretinal Photocoagulation and Cataract Surgery
- •10.12 Management of Cataract in Patients with Diabetic Retinopathy Undergoing Vitrectomy
- •10.13 Influence of Vitrectomy Surgery on Cataract Formation
- •10.15 Postoperative Endophthalmitis in Patients with Diabetic Retinopathy
- •10.16 Summary of Key Points
- •10.17 Future Directions
- •References
- •The Relationship of Diabetic Retinopathy and Glaucoma
- •11.1 Interaction of Diabetes and Glaucoma
- •11.2 Iris and Angle Neovascularization Pathoanatomy and Pathophysiology
- •11.3 Epidemiology
- •11.4 Clinical Detection
- •11.5 Classification
- •11.6 Risk Factors for Iris Neovascularization
- •11.7 Entry Site Neovascularization After Pars Plana Vitrectomy
- •11.8 Anterior Hyaloidal Fibrovascular Proliferation
- •11.9 Treatments for Iris Neovascularization
- •11.10 Modifiers of Behavior of Iris Neovascularization
- •11.11 Management of Neovascular Glaucoma
- •11.12 Summary of Key Points
- •11.13 Future Directions
- •References
- •The Cornea in Diabetes Mellitus
- •12.1 Introduction
- •12.2 Pathophysiology
- •12.3 Anatomy and Morphological Changes
- •12.4 Clinical Manifestations
- •12.5 Ocular Surgery
- •12.6 Treatment of Corneal Disease in Diabetes Mellitus
- •12.7 Conclusion
- •12.8 Summary of Key Points
- •12.9 Future Directions
- •References
- •Optic Nerve Disease in Diabetes Mellitus
- •13.1 Relevant Normal Optic Nerve Anatomy and Physiology
- •13.2 The Effect of Diabetes on the Optic Nerve
- •13.3 Nonarteritic Anterior Ischemic Optic Neuropathy and Diabetes
- •13.4 Diabetic Papillopathy
- •13.5 Disk Edema Associated with Vitreous Traction
- •13.6 Superior Segmental Optic Hypoplasia (Topless Optic Disk Syndrome)
- •13.7 Wolfram Syndrome
- •13.8 Summary of Key Points
- •13.9 Future Directions
- •References
- •Screening for Diabetic Retinopathy
- •14.1 Introduction
- •14.2 Who Does Not Need to Be Screened
- •14.5 Screening with Dilated Ophthalmoscopy by Ophthalmic Technicians or Optometrists
- •14.6 Screening with Dilated Ophthalmoscopy by Ophthalmologists
- •14.7 Screening with Dilated Ophthalmoscopy by Retina Specialists
- •14.8 Photographic Screening
- •14.9 Nonmydriatic Photography
- •14.10 Mydriatic Photography
- •14.11 Risk Factors for Ungradable Photographs
- •14.12 Number of Photographic Fields
- •14.13 Criteria for Referral
- •14.14 Obstacles to the Use of Teleophthalmic Screening Methods
- •14.15 Combination Methods of Screening
- •14.16 Case Yield Rates
- •14.17 Compliance with Recommendation to Be Seen by an Ophthalmologist
- •14.18 Intravenous Fluorescein Angiography and Oral Fluorescein Angioscopy
- •14.19 Automated Fundus Image Interpretation
- •14.20 Subgroups Needing Enhanced Screening Efforts
- •14.21 Screening in Pregnancy
- •14.22 Economic Considerations
- •14.23 Comparisons of the Screening Methods
- •14.24 Accountability of Screening Programs
- •14.25 Summary of Key Points
- •14.26 Future Directions
- •References
- •Practical Concerns with Ethical Dimensions in the Management of Diabetic Retinopathy
- •15.1 Incorporating Ancillary Testing in the Management of Patients with Diabetic Retinopathy
- •15.2.1 Case 1
- •15.2.2 Case 2
- •15.4 Working in a Managed Care Environment (Capitation)
- •15.5 Interactions with Medical Industry
- •15.7 Comanagement of Patients
- •15.9 Summary of Key Points
- •15.10 Future Directions
- •References
- •Clinical Examples in Managing Diabetic Retinopathy
- •16.1.1 Discussion
- •16.2 Case 2: Bilateral Proliferative Diabetic Retinopathy with Acute Vitreous Hemorrhage in One Eye and a Chronic Traction Retinal Detachment in the Other Eye
- •16.2.1 Discussion
- •16.2.2 Opinion 1
- •16.2.3 Opinion 2
- •16.2.4 Opinion 3
- •16.3 Case 3: Sight Threatening Diabetic Retinopathy in a Patient with Concomitant Medical and Socioeconomic Problems
- •16.3.1 Discussion
- •16.4 Case 4: Asymptomatic Retinal Detachment Following Vitrectomy in a Patient Who Has Had Panretinal Laser Photocoagulation
- •16.4.1 Discussion
- •16.5 Case 5: Management of Progressive Vitreous Hemorrhage Following Scatter Photocoagulation for Proliferative Diabetic Retinopathy
- •16.5.1 Discussion
- •16.6.1 Discussion
- •16.7 Case 7: Proliferative Diabetic Retinopathy with Macular Traction and Ischemia
- •16.7.1 Discussion
- •16.8 Case 8: What Is Maximal Focal/Grid Laser Photocoagulation for Diabetic Macular Edema?
- •16.8.1 Definition of the Problem
- •16.8.2 Discussion
- •16.9 Case 9: What Independent Information Does Macular Perfusion Add to Patient Management in Diabetic Retinopathy?
- •16.9.1 Discussion
- •16.10 Case 10: Macular Edema Following Panretinal Photocoagulation for Proliferative Diabetic Retinopathy
- •16.10.1 Discussion
- •16.11 Case 11: Diabetic Macular Edema with a Subfoveal Scar
- •16.11.1 Discussion
- •16.12.1 Definition of the Problem
- •16.12.2 Discussion
- •16.13.1 Definition of the Problem
- •16.13.2 Discussion
- •16.14 Case 14: How Is Diabetic Macular Ischemia Related to Visual Acuity?
- •16.14.1 Definition of the Problem
- •16.14.2 Discussion
- •References
- •Subject Index
152 |
D.J. Browning |
|
|
Fig. 7.13 Schematic summarizing the mechanisms of action of the various treatments for diabetic macular edema. The color-filled blocks represent different treatment modalities for DME. Adapted and expanded from Stefansson24
Intravitreal triamcinolone
Decreased leukostasis and ischemia
Intravitreal anti
VEGF drugs
Vitrectomy
|
Laser |
|
|
|
Vitrectomy |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thermal |
|
|
|
|
|
||
|
|
|
|
|
|
|||
coagulation of |
|
Fluid currents carry oxygen from |
||||||
|
RPE and |
|
||||||
|
|
well perfused areas to ischemic |
||||||
photoreceptors |
|
|||||||
|
|
areas of retina |
||||||
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Decreased oxygen |
|
|
|
|
|
|||
consumption of |
|
|
|
|
|
|||
|
outer retina |
|
|
|
|
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Choroidal oxygen |
|
|
|
|
|
|||
diffuses through |
|
|
|
|
|
|||
laser scars and |
|
|
|
|
|
|||
reaches inner retina |
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Increased oxygen tension of inner retina
Decreased
VEGF
production
Autoregulatory arteriolar vasoconstriction
Decreased
concentration of
unblocked VEGF Decreased hydrostatic pressure in capillaries
and venules
|
|
|
|
|
Decreased |
|
|
|
|
|
|
|
|
|
|
permeability |
|
Decreased water flux from |
|||||
|
|
|
|
|
of vessels |
|
|
vascular to tissue |
|||
|
|
|
|
|
|
|
|
|
compartment (Starling) |
||
Release |
|
|
|
|
|
|
|
|
|
||
macular |
|
|
|
|
|
|
|
|
|
||
traction |
|
|
|
Decreased Edema Formation |
|||||||
|
|
|
|
|
|
||||||
|
|
|
|
|
|
|
|
|
|
|
|
the Muller cell but not out of it. In addition, Muller cells have a bidirectional potassium channel called Kir4.1 that allows Muller cell intracellular potassium to flow into vessels around which Muller cell processes are wrapped (Fig. 7.14). In animal models of diabetes, there is downregulation of Kir4.1. Diabetic Muller cells in these models continue to take up potassium from the extracellular space but cannot discharge the potassium into the retinal microvessels. Because water osmotically follows solute, the Muller cells swell, a situation termed intracellular edema. In addition, a dysregulated polyol pathway activated by chronic hyperglycemia in diabetes is thought to be associated with accumulation of intracellular osmotically active solutes that draw in water and cause cellular swelling.54,93 Whereas the evidence for
intracellular edema appears to be substantial in dis-
eases of the brain, models for intracellular edema in the retina have been less well investigated.92,94
7.4 Clinical Definitions
There are several definitions important for understanding the literature on diabetic macular edema.
Diabetic Macular Edema – retinal thickening within 1 disk diameter of the center of the macula or definite hard exudates in this region.4 This definition used in the Early Treatment Diabetic Retinopathy Study (ETDRS) differs from some other definitions in which the radius may be 2 disk diameters
7 Diabetic Macular Edema |
153 |
|
|
Fig. 7.14 Schematic depicting pathways for water transport in the retina. Water is generated in the retina by oxidative synthesis of adenosine 50-triphosphate (ATP) that generates carbon dioxide and water (H2O).The Muller cell has processes that wrap around retinal microvessels. Bidirectional potassium channels called Kir4.1 are present in the Muller cell membranes abutting these microvessels. Muller cells also possess unidirectional potassium channels called Kir2.1 abutting the extracellular space that allows passage of potassium from the neuroretinal cells into the Muller cell.
Aquaporin 4 (AQ4) water channels allow the osmotic co-transport of water to follow potassium movement. The retinal pigment epithelium also actively transports potassium and chloride from the retina to the choroid with water cotransport occurring via aquaporin1 (AQ1) channels. In diabetes, the Kir4.1 channels are decreased, but not the KIR2.1 unidirectional potassium channels or the RPE potassium transport channels. The net effect is Muller cell swelling – intracellular edema. Reproduced with permission from Reichenbach and colleagues92
and in which the hard exudates criterion may be omitted. For epidemiologic purposes, some studies also classify an eye as having DME if there are macular photocoagulation scars to indicate previous treatment even if no macular thickening is present.95
Clinically Significant Macular Edema (CSME) – the situation in which at least one of the following criteria is fulfilled:
a.Retinal thickening within 500 mm of the center of the macula
b.Hard exudates within 500 mm of the center of the macula with adjacent retinal thickening
c.One disk area of retinal thickening any part of
which is within 1 disk diameter of the center of the macula4
Clinically Significant Macular Edema – Terminologic Vagary
The definition of CSME was created in the ETDRS and was based on analysis of stereoscopic fundus photographs of the macula by trained nonphysician graders. The term, however, was used and continues to be used in a clinical sense as well. The eyes in the ETDRS were classified and
154 |
D.J. Browning |
|
|
randomized at baseline based on fundus photographic gradings, but at follow-up visits, retreatment decisions were made based on clinical examinations at the slit lamp. Thus, although there is one-term CSME, there are two methods of determining it.
The definition of CSME has been termed ‘‘complex’’ and ‘‘difficult to apply precisely in clinical practice’’ even by its originators.96 Most published reproducibility statistics apply to the term as construed from color fundus photography.97 There are no statistics published for the reproducibility of CSME as determined at the slit lamp by different clinicians, and yet the definition is widely used in clinical ophthalmology as the threshold for treatment of DME. To confidently extrapolate the results of the ETDRS trial to routine clinical practice, it would seem of interest to know how photographically graded CSME and clinically graded CSME compare. In one study on this topic, clinical diagnosis had a sensitivity of 24% relative to stereo photography.96 In other studies, the chance corrected agreement between clinical diagnosis and stereo fundus photography has ranged from 0.31 to 0.55.96,98 Among the disagreements between ophthalmoscopy and analysis of fundus photographs, undercalls by ophthalmoscopy were more common than overcalls (88 and 12%, respectively).96 In the ETDRS itself, a much more tightly controlled study environment in which the retina specialists who were involved were the same ones who defined the term CSME, the kappa statistic for clinical examination with a fundus contact lens compared to analysis of stereo fundus photographs was 0.61.99 In general, clinical detection of CSME is less sensitive than detection by analyzing stereo fundus photographs. The evidence suggests that treating DME based on clinical estimation of the presence of CSME probably leads to a degree of undertreatment compared to treatment decisions based on analysis of stereoscopic fundus photographs.
7.5Focal and Diffuse Diabetic Macular Edema
The terms focal and diffuse are used frequently to differentiate two types of DME, although these
terms have not been defined consistently in the litera- ture.100–121 Focal edema is said to arise from micro-
aneurysms (Fig. 7.15), whereas diffuse edema is said
to arise from generally dilated and hyperpermeable capillaries throughout the macula (Fig. 7.16).122,123
The difficulty comes in translating this simple concept into an operationally reproducible methodology in clinical practice. Focal DME defined in a variety of ways has been reported to be more common than diffuse DME, but many cases of DME subjected to
these definitions have mixed features making a clear distinction difficult (Fig. 7.17).79,116,124–127 Additional
confusion may arise because the term focal is used to describe a technique of applying laser directly to microaneurysms when treating DME with focal/grid photocoagulation.4
In general, paucity of lipid exudates has been associated with diffuse edema in ophthalmoscopic
definitions, whereas presence of lipid and lipid
rings has been associated with focal edema.79,102,112,128–132 Definitions involving color
fundus photographs often involve area criteria, and the criteria vary among studies.
In the ETDRS, DME was defined clinically from stereoscopic biomicroscopy without reference to focal or diffuse descriptions of that clinical examination. However, fluorescein angiograms were analyzed by a reading center and the source of fluorescein leakage was graded categorically by proportion of leakage originating from microaneurysms for classification of edema as focal or diffuse. Eyes with 67% of leakage associated with microaneurysms were classified as focal, those with 33–66% of leakage associated with microaneurysms as intermediate, and those with <33% of leakage associated with microaneurysms as diffuse.133,134 The reproducibility of grading fluorescein angiograms for leakage source has been classified as only fair by the ETDRS authors.133 Others are less circumspect. Blair and colleagues state ‘‘it is notoriously difficult to quantify leakage on fluorescein angiograms.’’29
7 Diabetic Macular Edema |
|
155 |
|
|
|
a |
b |
c |
d
Fig. 7.15 (a) Focal diabetic macular edema is often described as arising from microaneurysms and having an association with lipid exudates, often in circinate rings. In this red-free photograph, lipid exudates surround a large microaneurysm temporal to the center of the macula. (b) The mid-phase fluorescein angiogram shows the
microaneurysm responsible for the exudates. The exudates are not apparent on fluorescein angiography. (c) The latephase fluorescein angiogram shows fluorescein leakage from the microaneurysm. (d) The horizontal radial line scan OCT image shows parafoveal cystoid thickening of the macula
a |
b |
c |
Fig. 7.16 (a) Diffuse diabetic macular edema is often described as arising from dilated capillaries throughout the posterior pole, but not from microaneurysms, involving large areas of the macula, involving the center of the macula, and associated with few lipid exudates.The usage of the term
diffuse, however, is inconsistent in the published literature. This color fundus photograph shows few lipid exudates. (b) Relatively few microaneurysms are seen relative to the amount of fluorescein leakage shown in the late frame (see c). (c) Profuse late leakage of fluorescein is present
Optical coherence tomography (OCT) can also be used to define edema as focal or diffuse. In the false color map, isolated islands of hot colors surrounded by larger areas of cool colors give a sense of focality, but this is subjective. Some have suggested that diffuse DME be understood to imply an increasing number of elevated subfields on the map display.135 This OCT-based characterization has not proven to
explain additional variability in visual acuity over that explained by central subfield mean thickness, age, or fluorescein leakage in the inner subfields nor has it been predictive of visual acuity outcomes at 1 year after focal photocoagulation.136
When clinicians are asked to classify DME as focal or diffuse, evidence suggests that their assessments differ from classifications used by photographic
156 |
D.J. Browning |
|
|
Fig. 7.17 Many eyes with diabetic macular edema have mixed characteristics with leakage from microaneurysms and dilated capillary segments, lipid exudates in some thickened areas and not others, and large areas of thickening, but not necessarily involving the center of the macula. An example is shown. (a) A lipid ring is present superotemporally but other regions of thickened macula are free of lipid. (b) A midphase frame of the fluorescein angiogram does not show more
microaneurysms in the area of the lipid ring than in other areas without lipid. (c) A frame from the late phase of the fluorescein angiogram shows an area of leaky microaneurysms inferotemporal to the center of the macula without associated lipid of note. (d) The OCT shows that the fovea is only mildly thickened, a characteristic often associated with focal edema, yet with a large area of thickened macula, a characteristic often associated with diffuse edema
reading centers. In comparing a British prospective survey of laser treatment for DME in which clinicians graded DME and a Diabetic Retinopathy Clinical Research (DRCR) network clinical trial involving two methods of laser treatment for DME in which a reading center graded DME, there was a 27% discrepancy between fractions categorized as focal by the two studies.137 Although this might reflect different samples, it could also suggest that the clinical and photographic methods capture different information about these eyes, and suggests that caution is required in implicitly comparing statements about focal DME defined in different ways.
Many authors have claimed that diffuse DME is refractory to macular photocoagulation and that diffuse DME is a prognostic factor for poorer visual acuity at follow-up, but the evidence for these
claims has not come from prospective clinical trials and is weak.115,138 In some cases, the literature has
been misquoted, most frequently by claiming that the ETDRS showed that diffuse DME showed a
poorer response to focal/grid laser than focal DME.121,139 In fact, the ETDRS looked at the
source of fluorescein leakage as a possible factor that might modify the beneficial effect of photocoagulation for DME on the development of moderate
